Limits...
Peratrial Device Closure of Atrial Septal Defect UnderTransesophageal Echocardiographic Guidance without Fluoroscopy Compared to Conventional On-Pump Surgical Closure

View Article: PubMed Central - PubMed

ABSTRACT

Objective: This study is designed to evaluate the advantages between peratrial deviceclosure under transesophageal echocardiographic guidance and open heartsurgery in atrial septal defect.

Methods: From November 2011 to September 2014, 28 patients with atrial septal defectwere treated. Fourteen patients received peratrial device closure undertransesophageal echocardiographic guidance (TEE group) and 14 patientsreceived cardiopulmonary bypass (CPB group). Clinical parameters duringintraoperative and postoperative periods were examined.

Results: All patients recovered after surgery without serious complications. Comparedwith that in CPB group, clinical observations in TEE group showedsignificant decreases in the operation time (193.6±35.5vs. 77.4±22.7 min, P<0.05),periods in intensive care unit (31.6±23.3 vs.17.5±8.1 hours, P<0.05), fluid volume afteroperation (502.5±439.3 vs. 32.5±7.3 ml,P<0.05), postoperative length of hospital stay(8.9±2.8 vs. 6.8±2.4 days,P<0.05) and total hospitalization cost(7205.9±1617.6 vs. 5882.3±441.2 $,P<0.05).

Conclusion: The peratrial device closure of atrial septal defect under transesophagealechocardiographic guidance is a mini-invasive, simple, safe and effectiveintervention. Its use in the clinical practice should be encouraged.

No MeSH data available.


Appearance and structure of Lifetech ASD Occluder.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5382899&req=5

f1: Appearance and structure of Lifetech ASD Occluder.

Mentions: ASD occluders were provided by Lifetech Scientific (Shenzhen Co., China) (Figure 1). The ASD occluder is covered by apolyethylene terephthalate (PET) membrane that minimizes the chance of clotformation and has a small volume to get into lower profile sheath. ASD occludershave safe long-term biocompatibility and promote the growth of endothelialtissue, lessen thrombus complication and effectively reduce atrioventricularblock occurrence.


Peratrial Device Closure of Atrial Septal Defect UnderTransesophageal Echocardiographic Guidance without Fluoroscopy Compared to Conventional On-Pump Surgical Closure
Appearance and structure of Lifetech ASD Occluder.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5382899&req=5

f1: Appearance and structure of Lifetech ASD Occluder.
Mentions: ASD occluders were provided by Lifetech Scientific (Shenzhen Co., China) (Figure 1). The ASD occluder is covered by apolyethylene terephthalate (PET) membrane that minimizes the chance of clotformation and has a small volume to get into lower profile sheath. ASD occludershave safe long-term biocompatibility and promote the growth of endothelialtissue, lessen thrombus complication and effectively reduce atrioventricularblock occurrence.

View Article: PubMed Central - PubMed

ABSTRACT

Objective: This study is designed to evaluate the advantages between peratrial deviceclosure under transesophageal echocardiographic guidance and open heartsurgery in atrial septal defect.

Methods: From November 2011 to September 2014, 28 patients with atrial septal defectwere treated. Fourteen patients received peratrial device closure undertransesophageal echocardiographic guidance (TEE group) and 14 patientsreceived cardiopulmonary bypass (CPB group). Clinical parameters duringintraoperative and postoperative periods were examined.

Results: All patients recovered after surgery without serious complications. Comparedwith that in CPB group, clinical observations in TEE group showedsignificant decreases in the operation time (193.6±35.5vs. 77.4±22.7 min, P<0.05),periods in intensive care unit (31.6±23.3 vs.17.5±8.1 hours, P<0.05), fluid volume afteroperation (502.5±439.3 vs. 32.5±7.3 ml,P<0.05), postoperative length of hospital stay(8.9±2.8 vs. 6.8±2.4 days,P<0.05) and total hospitalization cost(7205.9±1617.6 vs. 5882.3±441.2 $,P<0.05).

Conclusion: The peratrial device closure of atrial septal defect under transesophagealechocardiographic guidance is a mini-invasive, simple, safe and effectiveintervention. Its use in the clinical practice should be encouraged.

No MeSH data available.